Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Sage Therapeutics, Inc. < Previous 1 2 Next > Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress May 02, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023 April 18, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Present at the Stifel 2023 CNS Days March 22, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics Appoints Jessica Federer to Board of Directors March 16, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone March 08, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference February 28, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease February 22, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress February 16, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression February 06, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers BIIB SAGE Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023 February 02, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference January 08, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 January 03, 2023 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression December 06, 2022 From Sage Therapeutics, Inc. Via Business Wire Tickers BIIB SAGE Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference November 23, 2022 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone November 22, 2022 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference November 09, 2022 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress November 08, 2022 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022 October 25, 2022 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress October 17, 2022 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone September 19, 2022 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference September 02, 2022 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress August 02, 2022 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Present at Upcoming August Investor Conferences August 01, 2022 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022 July 19, 2022 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Present at Upcoming June Investor Conferences June 02, 2022 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints June 01, 2022 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference May 04, 2022 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress May 03, 2022 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD) May 02, 2022 From Sage Therapeutics, Inc. Via Business Wire Tickers BIIB SAGE Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022 April 19, 2022 From Sage Therapeutics, Inc. Via Business Wire Tickers SAGE < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
